Early-Stop trial tests new drug for painful, disfiguring skin sores
NCT ID NCT06092216
Summary
This study aimed to see if a drug called spesolimab could help heal severe, painful skin ulcers caused by a rare autoimmune condition called pyoderma gangrenosum. The drug, given by infusion every few weeks, works by blocking a specific part of the immune system thought to drive the inflammation. The trial was terminated early after enrolling only 5 participants, so its full results are unknown.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PYODERMA GANGRENOSUM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
Conditions
Explore the condition pages connected to this study.